Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. (Q45076113)
Jump to navigation
Jump to search
scientific article published in October 2004
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. |
scientific article published in October 2004 |
Statements
Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma (English)
Nicolaus Kröger
Jose A Perez-Simon
Han Myint
Hans Klingemann
Avichai Shimoni
Arnon Nagler
Rodrigo Martino
Adrian Alegre
Jose F Tomas
Rainer Schwerdtfeger
Michael Kiehl
Axel Fauser
Herbert Gottfried Sayer
Angel Leon
Tatjana Zabelina
Ronald Brand
Axel Rolf Zander
1 October 2004